Treatment of Chinese Patients with Advanced Gastric Cancer with Folfiri Followed by Folfox7 or the Reverse Sequence

F. Bi,Q. Li,C. Zhou,J. Yu,X. Cai,M. Qiu,J. Liu,C. Yi,D. Luo,F. Xu

DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.tps207

IF: 45.3

2010-01-01

Journal of Clinical Oncology

Abstract:TPS207 Background: A well-recognized standard first-line or salvage chemotherapy regimen for advanced or metastatic gastric cancer has not been established until now. Two regimen sequences—folinic acid, 5-fluorouracil (FU), and irinotecan (mFOLFIRI) followed by folinic acid, FU, and oxaliplatin (mFOLFOX7; arm A), and mFOLFOX7 followed by mFOLFIRI (arm B)—were evaluated for their antitumor activity and toxicity in Chinese patients (pts) with locally advanced or metastatic gastric cancer. Methods: Previously untreated pts between age 18 and 75 with an ECOG performance status of 0-2 and life expectancy > 4 months were eligible if they had histologically proven gastric or gastroesophageal junction adenocarcinoma with at least one site of unidimensionally measurable disease (RECIST), adequate bone marrow function (hemoglobin ≥90 g/L, absolute neutrophil count of ≥2.0×109 cells/L, and platelet count of ≥100×109 cells/L), hepatic function (alkaline phosphatases ≤3 upper limits of normal [UNL], total bilirubin ≤1.5 UNL, AST and ALT ≤3UNL) and renal function (creatinine ≤135umol/L). Previous adjuvant chemotherapy, if given, must have been completed at least 6 months before inclusion. Pts were randomized (1:1) according to the following sequences: a 2-hour infusion of folinic acid 200 mg/m2 followed by 46-hour infusion of FU 2,400 mg/m2 every 2 weeks, either with irinotecan 150 mg/m2 or with oxaliplatin 85 mg/m2 as a 2-hour infusion on day 1. Toxicity evaluations were based on the National Cancer Institute Common Toxicity Criteria for Adverse Events v3.0. Radiological evaluations were conducted at base line and after every two courses. At progression, irinotecan was replaced by oxaliplatin (arm A), or oxaliplatin by irinotecan (arm B). Primary endpoint was progression-free survival. Secondary endpoints were overall survival, response rate, and safety. Randomization was performed using a minimization technique, stratifying patients by center and by presence or absence of measurable disease. The planned sample size is 100 in each arm, considering two-sided log-rank test to have 80% power to detect a 20% difference in the proportion of patients without progression at 8 months. No significant financial relationships to disclose.